Company Overview

Harmony Biosciences Holdings, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological and sleep-related disorders. The company operates within the biotechnology and specialty pharmaceutical industries, with an emphasis on orphan and underserved indications. Its core business centers on identifying clinically differentiated assets, advancing them through targeted development, and commercializing them primarily in the United States.

Harmony’s primary revenue driver is WAKIX® (pitolisant), a first-in-class histamine 3 (H3) receptor antagonist/inverse agonist approved in the U.S. for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company serves a specialized physician and patient population within sleep medicine and neurology. Strategically, Harmony differentiates itself through a focused commercial model in rare diseases, long product lifecycle management, and licensing arrangements that allow it to leverage established science while controlling U.S. commercialization. Founded in 2017, Harmony completed its initial public offering in 2020 and has since evolved into a profitable, commercial-stage biopharmaceutical company.

Business Operations

Harmony operates as a single-reportable-segment company focused on the development and commercialization of rare disease therapies, with substantially all revenue generated from U.S. sales of WAKIX®. The company holds U.S. commercialization rights to pitolisant under a long-term license from Bioprojet Pharma, the originator of the compound. Commercial activities include physician education, patient support programs, and payer engagement, supported by a specialty sales force.

While Harmony’s commercial operations are concentrated in the United States, its development activities include clinical trials and regulatory interactions that may involve international sites. The company does not currently market products outside the U.S. and does not operate manufacturing facilities, relying instead on third-party manufacturers and supply chain partners. Harmony has expanded its operational scope through acquisitions and licensing deals to build a pipeline beyond narcolepsy; however, details on certain acquired development-stage assets and their timelines remain evolving, and some program-specific information is inconclusive based on available public sources.

Strategic Position & Investments

Harmony’s strategy emphasizes sustainable growth through lifecycle expansion of WAKIX®, including additional indications and pediatric formulations, as well as the acquisition or in-licensing of late-stage or commercially ready rare disease assets. The company has publicly stated its intent to deploy capital toward assets that fit its core competencies in neurology and rare disorders and that can leverage its existing commercial infrastructure.

In line with this strategy, Harmony has made notable investments and acquisitions to expand its pipeline, including the acquisition of Zynerba Pharmaceuticals, which added the investigational asset Zygel™ for Fragile X syndrome and other neuropsychiatric indications. Harmony continues to evaluate emerging therapies in rare neurological conditions, though the ultimate commercial viability and regulatory outcomes of certain pipeline programs remain uncertain based on publicly available data.

Geographic Footprint

Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania, and its commercial activities are primarily concentrated in the United States, which represents substantially all current revenue. The company’s U.S.-centric focus reflects its licensing structure and regulatory approvals, as WAKIX® is commercially marketed only in the U.S. by Harmony.

Internationally, Harmony maintains strategic relationships and contractual ties through its licensing agreements, particularly with European partners, but it does not directly conduct commercial operations outside North America. Clinical development activities and manufacturing partnerships may involve vendors and trial sites across Europe and other regions, providing the company with indirect international operational exposure.

Leadership & Governance

Harmony Biosciences is led by an executive team with experience in rare disease commercialization, neurology, and public biopharmaceutical company management. The leadership emphasizes disciplined capital allocation, patient-focused development, and long-term value creation through durable rare disease franchises.

Key executives include:

• Jeffrey M. Dayno – President and Chief Executive Officer
• Sandip Kapadia – Chief Financial Officer
• Matt Feczko – Chief Commercial Officer
• Kathy Roth – Chief Regulatory and Quality Officer

The leadership team’s strategic vision centers on building Harmony into a leading rare neurological disease company by maximizing the value of its existing products while selectively expanding its pipeline through targeted acquisitions and internal development.